Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma

Blood

Volumn 119, Issue 7, 2012, Pages 1665-1670

  Moskowitz, Craig H ^a   Matasar, Matt J ^a   Zelenetz, Andrew D ^a   Nimer, Stephen D ^a   Gerecitano, John ^a   Hamlin, Paul ^a   Horwitz, Steven ^a   Moskowitz, Alison J ^a   Noy, Ariela ^a   Palomba, Lia ^a   Perales, Miguel Angel ^a   Portlock, Carol ^a   Straus, David ^a   Maragulia, Jocelyn C ^a   Schoder, Heiko ^a   Yahalom, Joachim ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CARMUSTINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; IFOSFAMIDE; MESNA; NAVELBINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANAPHYLAXIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CATHETER INFECTION; CATHETER THROMBOSIS; CLOSTRIDIUM DIFFICILE INFECTION; CONTINUOUS INFUSION; CONTROLLED STUDY; DEPRESSION; DRUG SAFETY; ESOPHAGITIS; EVENT FREE SURVIVAL; FEBRILE NEUTROPENIA; FEMALE; GRAFT VERSUS HOST REACTION; HEART TAMPONADE; HERPES ZOSTER; HODGKIN DISEASE; HUMAN; LYMPH NODE IRRADIATION; MALE; MULTIPLE ORGAN FAILURE; MYELODYSPLASTIC SYNDROME; PHASE 2 CLINICAL TRIAL; PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; RADIATION PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; SALVAGE THERAPY; TREATMENT PLANNING; TREATMENT RESPONSE; VIRUS MENINGITIS;

EID: 84857497150     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-10-388058     Document Type: Article

References (16)

1. Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet. 1993;341(8852):1051-1054. (Pubitemid 23114397)
2. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet. 2002;359(9323):2065-2071. (Pubitemid 34680969)
3. Kuruvilla J, Keating A, Crump M. How I treat relapsed and refractory Hodgkin lymphoma. Blood. 2011;117(16):4208-4217.
4. Moskowitz CH, Nimer SD, Zelenetz AD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood. 2001;97(3):616-623. (Pubitemid 32113392)
5. Goodman KA, Riedel E, Serrano V, Gulati S, Moskowitz CH, Yahalom J. Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin's lymphoma. J Clin Oncol. 2008;26(32):5240-5247.
6. Moskowitz CH, Yahalom J, Zelenetz AD, et al. High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging. Br J Haematol. 2010;148(6):890-897.
7. Moskowitz CH, Kewalramani T, Nimer SD, Gonzalez M, Zelenetz AD, Yahalom J. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. Br J Haematol. 2004;124(5):645-652. (Pubitemid 38297098)
8. Moskowitz AJ, Yahalom J, Kewalramani T, et al. Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood. 2010;116(23):4934-4937.
9. Smeltzer JP, Cashen AF, Zhang Q, et al. Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation. Biol Blood Marrow Transplant. 2011;17(11):1646-1652.
10. Lister TA, Crowther D. Staging for Hodgkin's disease. Semin Oncol. 1990;17(6):696-703.
11. Moskowitz CH, Bertino JR, Glassman JR, et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor- cell mobilization regimen for transplanteligible patients with non-Hodgkin's lymphoma. J Clin Oncol. 1999;17(12):3776-3785.
12. Evens AM, Hutchings M, Diehl V. Treatment of Hodgkin lymphoma: the past, present, and future. Nat Clin Pract Oncol. 2008;5(9):543-556.
13. Bartlett NL, Niedzwiecki D, Johnson JL, et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol. 2007;18(6):1071-1079. (Pubitemid 47053777)
14. Peggs KS, Sureda A, Qian W, et al. Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes. Br J Haematol. 2007;139(1): 70-80. (Pubitemid 47389932)
15. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363(19): 1812-1821.
16. Younes A. Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2009; 2009:507-519.